SMAD7

Progenity Provides Corporate Update and Reports Third Quarter 2021 Financial Results

Retrieved on: 
Wednesday, November 10, 2021
Gastrointestinal tract, Audit committee, Industry, Private Securities Litigation Reform Act, Net, Financial condition report, Genomics, Health, Method, Ulcerative colitis, SMAD7, Epigenomics, Disease, Trial of the century, COVID-19, Research, DDS, Comparison, Proteomics, IP, Human, GI, Board, Partnership, Biotechnology, GLOBE, Metabolomics, JAK, Therapy, Board of directors, SEC, Drug discovery, Diagnosis, Webcast, Precision medicine, Analysis, Result, Patent, Nasdaq, Intellectual property, Management, Pharmaceutical industry, Animal, Lithium, Reinsurance

SAN DIEGO, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today provided a corporate update and reported financial results for the third quarter ended September 30, 2021.

Key Points: 
  • Management will host conference call and webcast today at 4:30 p.m. Eastern / 1:30 p.m. Pacific
    SAN DIEGO, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today provided a corporate update andreported financial results for the third quarter ended September30, 2021.
  • Progenity also received $19.6 million in gross proceeds from warrant exercises in the second half of 2021 to date.
  • Operating expenses were $30.7 million for the three months ended September30, 2021, compared to $36.1 million for the three months ended June30, 2021.
  • Progenity will host a webcast and conference call to discuss the third quarter financial results and answer investment community questions today, Wednesday, November 10, 2021 at 4:30 p.m. Eastern / 1:30 p.m. Pacific.

Progenity Announces Several Patents Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Ingestible Therapeutics Technologies

Retrieved on: 
Wednesday, October 13, 2021
Janus, Safe harbor, Organic acid, Gastrointestinal disease, Technology, Integrin, Peptide, Blood, Adalimumab, Private Securities Litigation Reform Act, Nasdaq, Liraglutide, Ulcerative colitis, Method, Protein, GI, IBD, Tissue, SEC, JAK, Therapy, Financial condition report, Result, USPTO, The O.C., United States Patent and Trademark Office, Disease, Ionis Pharmaceuticals, Proteomics, Metabolomics, Analysis, Patient, Epigenomics, GLOBE, DDS, Investment, Patent, Toxicity, Forward-looking statement, SAN, Tumor necrosis factor, Gastrointestinal tract, Inflammatory bowel disease, Safety, SMAD7, 1836 U.S. Patent Office fire, Genomics, COVID-19, Pharmaceutical industry, Vaccine

Progenitys Oral Biotherapeutic Delivery System (OBDS), currently under development, is designed for systemic, needle-free delivery of biotherapeutics via an ingestible device.

Key Points: 
  • Progenitys Oral Biotherapeutic Delivery System (OBDS), currently under development, is designed for systemic, needle-free delivery of biotherapeutics via an ingestible device.
  • We believe we hold one of the most robust ingestible device patent portfolios, said Eric dEsparbes, interim CEO of Progenity.
  • The addition of these recent patents further strengthens our intellectual property position and underscores our commitment to innovation in advancing therapeutic discovery, development, and delivery.
  • Progenitys Drug Delivery System (DDS) is an ingestible capsule designed for targeted delivery of therapeutics to improve treatment of gastrointestinal disease.